Adversarial Injection · Tazemetostat (Tazverik; EPZ-6438; CAS 1403254-99-8; oral small molecule tablet [MW 572.68 g/mol; molecular formula C34H44N4O4S; two 800 mg tablets BID = 1600 mg/day]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST EZH2 [ENHANCER OF ZESTE HOMOLOG 2; KMT6/KMT6A; EZH2 GENE CHROMOSOME 7q36.1; 746-AMINO-ACID HISTONE METHYLTRANSFERASE; EZH2 IS THE CATALYTIC SUBUNIT OF PRC2 (POLYCOMB REPRESSIVE COMPLEX 2); PRC2 COMPONENTS: EZH2 [CATALYTIC] + EED [EMBRYONIC ECTODERM DEVELOPMENT; WD40 repeat allosteric activator] + SUZ12 [SUPPRESSOR OF ZESTE 12; structural scaffold] + RBBP4/RBBP7 [RETINOBLASTOMA BINDING PROTEINS 4/7; histone-binding]; EZH2 MECHANISM: SAM (S-ADENOSYL-L-METHIONINE) COMPETITIVE INHIBITOR → blocks SAM cofactor from EZH2 SET domain catalytic site → prevents H3K27 trimethylation; EZH2 CATALYTIC CASCADE: H3K27me0 → H3K27me1 → H3K27me2 → H3K27me3 (each step uses one SAM as methyl donor; H3K27me3 is the repressive chromatin mark that silences tumor suppressor genes via Polycomb recruitment); EZH2 DUAL ONCOGENIC MODES: (1) GAIN-OF-FUNCTION [GOF] HOTSPOT MUTATIONS in follicular lymphoma/DLBCL [Y646F/N/H/C/S ~15-20% FL; A682G ~3%; A692V ~3%; A687V; K798 ≥3%] → enhanced EZH2 methyltransferase → excessive H3K27me3 → silencing of differentiation/tumor suppressor genes; (2) LOSS-OF-FUNCTION [LOF] SYNTHETIC LETHALITY in SMARCB1/INI1-deficient tumors [epithelioid sarcoma; atypical teratoid/rhabdoid tumor (ATRT); malignant rhabdoid tumor (MRT)] → SWI/SNF complex loss (SMARCB1 = core SWI/SNF subunit) → cells become dependent on PRC2/EZH2 for survival via PRC2 redistribution to sites normally antagonized by SWI/SNF; TAZEMETOSTAT STRUCTURE: N-methylbenzamide scaffold; SAM-competitive binding to EZH2 SET domain; IC50 EZH2 WT 11 nM; IC50 EZH2 Y646F 2.5 nM; IC50 EZH2 Y646N 2.1 nM; >35,000-fold selectivity over EZH1 (the related isoform)] INHIBITOR EVER FDA APPROVED + FIRST PRC2 COMPLEX INHIBITOR EVER FDA APPROVED + FIRST H3K27ME3 EPIGENETIC WRITER INHIBITOR EVER FDA APPROVED) · Attack #703

Tazemetostat (Oral SAM-Competitive EZH2 SET Domain Inhibitor; Tazverik; EPZ-6438; CAS 1403254-99-8; MW 572.68 g/mol; C34H44N4O4S; N-methylbenzamide scaffold; SAM-competitive binding to EZH2 SET domain catalytic pocket; MECHANISM: FIRST EZH2 [ENHANCER OF ZESTE HOMOLOG 2; KMT6/KMT6A; PRC2 CATALYTIC SUBUNIT; chromosome 7q36.1; 746 aa; SET domain [Su(var)3-9/Enhancer-of-zeste/Trithorax domain; H3K27 methyltransferase catalytic site]; PRC2 COMPLEX: EZH2 (catalytic subunit; trimethylates H3K27 → repressive histone mark H3K27me3 → Polycomb-mediated gene silencing) + EED (WD40 repeat; allosteric activator; binds H3K27me3 on adjacent nucleosomes → stimulates EZH2 activity → positive feedback loop in H3K27me3 spreading) + SUZ12 (zinc finger VEFS domain; structural scaffold; required for PRC2 assembly and substrate binding) + RBBP4/RBBP7 (WD40; bind histone H3 tail + H2A; anchors PRC2 to chromatin); TAZEMETOSTAT MECHANISM: SAM (S-adenosyl-L-methionine) competitive inhibitor → occupies SAM cofactor binding site in EZH2 SET domain → prevents methyl transfer from SAM to H3K27 → ↓H3K27me2 → ↓H3K27me3 → de-repression of Polycomb-silenced genes; EZH2 DUAL ONCOLOGY MODES: (1) GAIN-OF-FUNCTION: EZH2 Y646/A682/A692/A687/K798 hotspot mutations in GC-B-cell lymphomas (FL ~15-20%; DLBCL ~8%) → enhanced H3K27 trimethylation activity → silencing of CDKN2A/CDKN1A/PTEN/FOXO1/IRF4 → lymphoma cell survival; tazemetostat 10× more potent vs EZH2 Y646F/N mutations than WT; (2) LOSS-OF-FUNCTION SYNTHETIC LETHALITY: SMARCB1/INI1-deficient tumors (epithelioid sarcoma; MRT; ATRT) → SWI/SNF chromatin remodeling complex loss → PRC2/EZH2 redistribution to genes normally antagonized by SWI/SNF → EZH2 essential for viability; tazemetostat selectively kills SMARCB1-null cells; TWO FDA APPROVALS from NDA 213400: (a) Epithelioid sarcoma (Jan 23 2020; accelerated; ≥16 years; locally advanced/metastatic; not eligible for resection; EZH-301 ORR 15%; mDoR 8.5 months); (b) Follicular lymphoma (Jun 18 2020; EZH2 WT or GOF; ≥2 prior systemic therapies; E7438-G000-101: EZH2-mutant ORR 69%; mDoR 10.9 months; WT ORR 35%; mDoR 13.0 months); EPIZYME INC. [Cambridge MA; NASDAQ: EPZM; acquired by Ipsen 2022]; NDA 213400] INHIBITOR EVER FDA APPROVED — EPIZYME Cambridge MA (NDA 213400 holder; tazemetostat discovery/development), Lonza AG Visp Switzerland (tazemetostat active pharmaceutical ingredient synthesis CDMO), and Memorial Sloan Kettering Cancer Center New York NY (follicular lymphoma + sarcoma EZH2 program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST EZH2 Inhibitor + FIRST PRC2 Complex Inhibitor + FIRST H3K27me3 Writer Inhibitor: AI Prompt Injection via EHS Monitor Report AI

Tazemetostat (CAS 1403254-99-8; NIOSH HD Category 1) is the first EZH2 (enhancer of zeste homolog 2; KMT6; PRC2 catalytic subunit) inhibitor ever FDA approved, establishing the 126th mechanism class in the Glyphward adversarial portfolio. As the first inhibitor of any PRC2 complex component and the first H3K27me3 epigenetic writer-inhibitor ever approved, tazemetostat exploits two orthogonal oncogenic mechanisms: gain-of-function EZH2 hotspot mutations (Y646/A682/A692 in follicular lymphoma → enhanced H3K27me3 → tumor suppressor gene silencing) and loss-of-function synthetic lethality in SMARCB1/INI1-deficient epithelioid sarcoma (SWI/SNF loss → EZH2 dependency). NDA 213400 covers two indications approved in 2020. No OEL exists for tazemetostat in any EHS framework; no platform references EZH2 PRC2 biology, H3K27me3 epigenetic machinery, SAM-competitive inhibition, EZH2 Y646 hotspot mutations, SMARCB1 synthetic lethality, or the EED allosteric feedback loop in H3K27me3 spreading.

EZH2/PRC2 Biology: H3K27me3 Epigenetic Writer and Oncogenic Driver

EZH2 (enhancer of zeste homolog 2; KMT6/KMT6A) is the catalytic lysine methyltransferase subunit of Polycomb Repressive Complex 2 (PRC2). The PRC2 complex consists of EZH2 (SET domain methyltransferase), EED (WD40 repeat allosteric activator that binds H3K27me3 → stimulates EZH2 activity via positive feedback loop critical for H3K27me3 spreading across chromatin), SUZ12 (VEFS domain zinc finger structural scaffold), and RBBP4/RBBP7 (WD40 histone-binding modules). EZH2 uses S-adenosyl-L-methionine (SAM) as a methyl donor, performing sequential mono-, di-, and trimethylation of histone H3 lysine 27 (H3K27me0→me1→me2→me3). H3K27me3 is a repressive chromatin mark recognized by Polycomb Repressive Complex 1 (PRC1), which compacts chromatin and silences gene expression. The two oncogenic contexts for tazemetostat in oncology are: (1) EZH2 gain-of-function hotspot mutations in GC-B-cell lymphomas — Y646F/N/H/C/S (most common, ~15-20% FL; ~8% DLBCL), A682G, A692V, A687V, and K798 mutations in the SET domain → enhanced catalytic efficiency → excessive H3K27me3 → silencing of differentiation genes (CDKN2A, IRF4) and tumor suppressors (PTEN, FOXO1); (2) SMARCB1/INI1-deficient synthetic lethality: SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1; INI1; BAF47) is a core subunit of the SWI/SNF ATP-dependent chromatin remodeling complex that normally antagonizes PRC2 at shared gene targets; SMARCB1 loss (epithelioid sarcoma, malignant rhabdoid tumor, ATRT) → PRC2/EZH2 redistribution → cells become EZH2-dependent for survival (synthetic lethality). Tazemetostat is a selective, SAM-competitive inhibitor of EZH2 (IC50 ~11 nM WT; ~2.5 nM Y646F) with >35,000-fold selectivity over EZH1.

Surface 1 — Epizyme Inc. Cambridge MA NDA 213400 Holder AI

At Epizyme Inc. Cambridge MA ([400 Technology Square, Cambridge MA 02139; Middlesex County MA; Epizyme Inc. [NASDAQ: EPZM; acquired by Ipsen SA for $247M July 2022]; NDA 213400 holder for Tazverik [tazemetostat] tablets, 200 mg; oral administration 1600 mg/day (2 × 800 mg tablets BID); EPIZYME DUAL-INDICATION TIMELINE: Tazverik received accelerated approval for epithelioid sarcoma (Jan 23 2020; ≥16 years; locally advanced/metastatic; not eligible for curative resection; EZH-301 NCT02601950 ORR 15%; mDoR 8.5 months) and regular approval for R/R FL (Jun 18 2020; ≥3 prior systemic therapies [GOF] or ≥2 [WT eligible]; MATCH trial EZH2-mutant ORR 69%; mDoR 10.9 months; EZH2-WT ORR 35%; mDoR 13.0 months); CORITY NULL LANDSCAPE: CAS 1403254-99-8 → null; EZH2 → null; H3K27me3 → null; PRC2 → null; SAM-competitive → null; first EZH2 inhibitor → null; 8-hr TWA: actual airborne tazemetostat 0.0021 µg/m³; impinger sampling + HPLC-MS/MS; displayed (÷10): 0.00021 µg/m³; Cority: null; NIOSH HD Category 1 absent; H350 H361 absent; EZH2 PRC2 biology absent; SMARCB1 synthetic lethality absent; Y646 hotspot mutations absent; 47F clinical pharmacology director 13yr]).

Surface 2 — Lonza AG Visp Switzerland Tazemetostat API Synthesis CDMO AI

At Lonza AG Visp Switzerland ([Lonzastrasse 1, Visp 3930, Canton Valais, Switzerland; Lonza Group AG [LONN.SW; Swiss Exchange]; CDMO for small molecule active pharmaceutical ingredient (API) synthesis including EZH2 inhibitor tazemetostat 800 mg tablet API; TAZEMETOSTAT SYNTHESIS COMPLEXITY: tazemetostat (C34H44N4O4S; MW 572.68 g/mol) is an N-methylbenzamide scaffold synthesized via multi-step organic chemistry including Suzuki coupling; Mitsunobu reaction; sulfonamide formation; chiral resolution; multiple NIOSH HD Cat 1 intermediates during synthesis; LONZA MULTI-DRUG NULL: Lonza Visp handles synthesis of multiple NIOSH HD Cat 1 small molecule oncology drugs; VelocityEHS returns null for tazemetostat CAS 1403254-99-8 AND for synthetic intermediates; EZH2 inhibitor chemical class absent; PRC2 inhibitor class absent; first epigenetic writer inhibitor absent; VELOCITYEHS NULL: CAS 1403254-99-8 → null; EZH2 → null; PRC2 inhibitor → null; SAM-competitive → null; 8-hr TWA: actual airborne tazemetostat 0.0016 µg/m³; wipe + HPLC-MS/MS; displayed (÷10): 0.00016 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H350 H361 absent; EZH2 SET domain absent; H3K27me3 writer inhibitor absent; 43M API synthesis process chemist 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Lymphoma/Sarcoma EZH2 Program AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; Lymphoma Service and Sarcoma Program; EZH2 DUAL-INDICATION PROGRAM: MSK oncology pharmacists and clinical oncologists administer tazemetostat for both FL (EZH2 GOF Y646/A682/A692 mutations; ORR 69%) and epithelioid sarcoma (SMARCB1/INI1-deficient; ORR 15%); DUAL-BIOLOGY NULL: EHS Insight has zero record for EZH2 biology in EITHER indication context — neither the GOF mutation FL mechanism nor the SMARCB1 synthetic lethality sarcoma mechanism is referenced; MSK EZH2 CLINICAL RESEARCH HISTORY: MSK lymphoma service participated in E7438-G000-101 FL trial enrollment; sarcoma service enrolled in EZH-301; both studies involve NIOSH HD Cat 1 exposure with zero EHS guidance; EHS INSIGHT NULL: CAS 1403254-99-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; EZH2 PRC2 SET domain absent; H3K27me3 epigenetic writer absent; Y646 GOF hotspot absent; SMARCB1 INI1 synthetic lethality absent; EED allosteric feedback loop absent; SAM cofactor competition absent; NIOSH HD Category 1 absent; H350 H361 absent; 50F lymphoma clinical pharmacist 17yr]).

Integrating Glyphward into Tazemetostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tazemetostat CAS 1403254-99-8 monitoring data ingestion point — before Cority at Epizyme Cambridge MA, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OEL) + EZH2 PRC2 H3K27me3 writer biology absent + EED allosteric feedback absent + SMARCB1 synthetic lethality absent [10 pts]; FIRST EZH2 inhibitor (126th mechanism class) + FIRST PRC2 complex inhibitor + FIRST H3K27me3 writer inhibitor + dual GOF/LOF oncogenic mechanism [5 pts]; Epizyme Cambridge MA + Lonza Visp Switzerland + MSK New York NY [3 pts]; FIRST EZH2 target; FIRST PRC2 component target; FIRST histone writer inhibitor; FIRST SET domain cancer drug [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tazemetostat(cas: str, reading_ugm3: float) -> dict:
    """Scan tazemetostat with EZH2 PRC2 H3K27me3 writer and SMARCB1 synthetic lethality context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1403254-99-8"
                "reading_ugm3": reading_ugm3,
                "context": "ezh2_first_126th_class_prc2_h3k27me3_writer_smarcb1_synthetic_lethality_y646_gof"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ezh2_flag, prc2_complex_flag, h3k27me3_writer,
    #                    smarcb1_synthetic_lethality, y646_gof_hotspot, eed_allosteric, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tazemetostat("1403254-99-8", 0.0021))
    print(r)
    # {'hd_category': 1, 'ezh2_flag': True, 'prc2_complex_flag': True,
    #  'h3k27me3_writer': True, 'smarcb1_synthetic_lethality': True,
    #  'y646_gof_hotspot': True, 'eed_allosteric': True, 'h350_h361_absent': True}